Psychemedics Corporation Stock News

Psychemedics (NASDAQ: PMD) is one of 42 publicly-traded companies in the Medical laboratories industry, but how does it compare to its competitors? We will compare Psychemedics to related companies based on the strength of its risk, earnings, valuation, profitability, dividends, analyst recommendations and institutional ownership. Profitability This table compares Psychemedics and its competitors net margins, []

Psychemedics (NASDAQ: PMD) is one of 42 public companies in the Medical laboratories industry, but how does it contrast to its peers? We will compare Psychemedics to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, dividends, earnings and risk. Valuation and Earnings This table compares Psychemedics and its peers []

29% YoY revenue growth in Q3, margins surge.

Psychemedics (NASDAQ: PMD) is one of 42 public companies in the Medical laboratories industry, but how does it contrast to its competitors? We will compare Psychemedics to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, profitability, dividends and institutional ownership. Earnings & Valuation This table compares Psychemedics and its competitors []

Market-leading drug testing company, 30 years history, drug abuse increasing in the US. 13x P/E, 8% FCF yield on “normal” 2023 estimates.

ACTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second

MIAMI--(BUSINESS WIRE)---- $PMD--Montana Advisors issues open letter to Psychemedics CEO (Nasdaq: PMD): Dear Kubacki: It was a pleasure speaking with you two months ago via Zoom. I appreciate the time

ACTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first q

ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year fi

ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corpora

ACTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Andrew Limbek has joined the Company as Vice President, Controller.

ACTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020.